HIV/AIDS Vaccine

Hyperglycosylated gp120 mutants may induce broad humoral responses

Published in Vaccine Weekly, June 11th, 2003

by Michael Greer, senior medical writer - Polymorphic forms of the HIV coat protein gp120 may elicit broad humoral responses, researchers in the United States say.

"The ability to induce broadly neutralizing antibodies should be a key component of any forthcoming vaccine" against HIV, noted Ralph Pantophlet and colleagues at the Scripps Research Institute in La Jolla, California. However, "one potential vaccine candidate, monomeric gp120, has generally failed to elicit such antibodies."

A hyperglycosylated gp120 mutant preferentially bound to a broadly neutralizing antibody, and could form the basis for a more effective vaccine, Pantophlet and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry